famotidine has been researched along with Diffuse Large B-Cell Lymphoma in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hegazy, SK | 1 |
| El-Haggar, SM | 1 |
| Alhassanin, SA | 1 |
| El-Berri, EI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.[NCT03647072] | Phase 3 | 60 participants (Anticipated) | Interventional | 2018-08-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for famotidine and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cyclophosphamide; Doxorubicin; Fam | 2021 |